In Search for a Better Marker of Acute Pancreatitis—Third Time Lucky?

Viljoen, Adie; Twomey, Patrick J

doi:10.1373/clinchem.2011.173385

Cited by 11 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The search for serological parameters for the diagnosis of acute pancreatitis continues unabatedly [2,9,24,25]. Thus, the recent report of GP2 being a superior marker for acute pancreatitis serology deserves closer attention [18].…”

Section: Discussionmentioning

confidence: 99%

Serological diagnosis and prognosis of severe acute pancreatitis by analysis of serum glycoprotein 2

Roggenbuck

Goihl

Hanack

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Serological diagnosis and prognosis of severe acute pancreatitis by analysis of serum glycoprotein 2 DOI 10.1515/cclm-2016-0797 Received September 6, 2016 accepted October 10, 2016; previously published online November 12, 2016 Abstract Background: Glycoprotein 2 (GP2), the pancreatic major zymogen granule membrane glycoprotein, was reported to be elevated in acute pancreatitis in animal models. Methods: Enzyme-linked immunosorbent assays (ELISAs) were developed to evaluate human glycoprotein 2 isoform alpha (GP2a) and total GP2 (GP2t) as specific markers for acute pancreatitis in sera of 153 patients with acute pancreatitis, 26 with chronic pancreatitis, 125 with pancreatic neoplasms, 324 with non-pancreatic neoplasms, 109 patients with liver/biliary disease, 67 with gastrointestinal disease, and 101 healthy subjects. GP2a and GP2t levels were correlated with procalcitonin and C-reactive protein in 152 and 146 follow-up samples of acute pancreatitis patients, respectively.

show abstract

Section: Discussionmentioning

confidence: 99%

Serological diagnosis and prognosis of severe acute pancreatitis by analysis of serum glycoprotein 2

Roggenbuck

Goihl

Hanack

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…There is no gold standard test available to diagnose AP at present. 2,3 Calcium plays a central role in the pathogenesis of pancreatitis and our understanding in this field is still evolving. Calcium is required for normal secretory function of the pancreatic acinar cells, but these signals are transient and mainly confined to apical pole.…”

Section: Introductionmentioning

confidence: 99%

Role of total calcium and corrected calcium in comparisons with computed tomography to predict severity of acute pancreatitis

Thakur¹,

Goyal²,

Aggarwal³

et al. 2020

Int Surg J

View full text Add to dashboard Cite

Background: The objective of the study was to evaluate corrected calcium levels in patient of acute pancreatitis and to evaluate role of corrected calcium as predictor of severity in acute pancreatitis in comparison to computed tomography (CT) scan.Methods: The study was conducted in Department of Biochemistry of G.G.S Medical College in collaboration with the Department of Surgery and Department of Radio diagnosis. 50 patients, with clinical diagnosis of acute pancreatitis, attending the Inpatient Department of Department of Surgery, were taken. 50 patients, of either sex of 18 to 70 age groups suffering from acute pancreatitis were enrolled for the study.Results: On exploring the data, highly significant negative correlation found between CT severity index (CTSI) and serum calcium (p≤0.001; r value=-0.520) whereas the non-significant correlation found between CTSI and amylase (p=0.778; r value=-0.041). The corrected calcium and CTSI shows highly negative significant correlation (p≤0.001; r value=-0.654). Serum albumin with CTSI also shows significant correlation (p=0.006; r value=0.385). But no significant association with lipase (p≥0.05).Conclusions: We observed that corrected calcium and calcium is better and alternative marker for predicating the severity of disease because corrected calcium and calcium is having good positive predictive value to indicate progression of damage and also a highly significant negative predictive value to rule out severity of acute pancreatitis.

show abstract

“…[1] While most cases of pancreatitis pass within a week from clinical presentation, 2-15% of cases may lead to death. [1][2][3] Diagnosis generally follows patient presentation with severe abdominal pain, nausea, and/or vomiting, and begins by laboratory measurement of serum amylase or lipase activity, [4] followed by confirmation of inflammation in the pancreas using imaging modalities such as ultrasound (US) and computer-aided tomography (CT). The use of amylase and lipase activity as enzyme biomarkers, though valuable, are hardly conclusive in the diagnosis of pancreatitis, and may remain at normal levels or be only slightly elevated even in severe cases of acute pancreatitis.…”

Section: Introductionmentioning

confidence: 99%

“…[5,6] The serum levels of amylase and lipase are dependent both on production and clearance, and may be elevated in other conditions, including cholecystitis, intestinal obstruction, ischemia, peptic ulcer disease, appendicitis, and gynecologic presentations, as well as in patients where renal function is compromised. [4,7] While lipase is generally considered the more reliable marker, [x] many clinical chemistry units are only equipped to measure amylase. These issues are compounded by long turnaround times for blood testing, limiting the ability of the physician to make timely decisions.…”

Section: Introductionmentioning

confidence: 99%

Phospholipase A2 as a point of care alternative to serum amylase and pancreatic lipase

et al. 2016

View full text Add to dashboard Cite

Acute pancreatitis is a relatively common and potentially fatal condition, but the presenting symptoms are non-specific and diagnosis relies largely on the measurement of amylase activity by the hospital clinical laboratory. In this work we develop a point of care test for pancreatitis measuring concentration of secretory phospholipase A2 group IB (sPLA2-IB). Novel antibodies for sPLA2-IB were raised and used to design an ELISA and a lateral flow device (LFD) for the point of care measurement of sPLA2-IB concentration, which was compared to pancreatic amylase activity, lipase activity, and sPLA2-IB activity in 153 serum samples. 98 of these samples were obtained from the pathology unit of a major hospital and classified retrospectively according to presence or absence of pancreatitis, and the remaining 55 were obtained from commercial sources to serve as high lipase (n = 20), CA19-9 positive (n = 15), and healthy (n = 20) controls. sPLA2-IB concentration correlated well with the serum activity of both amylase and lipase, and performed at least as well as either markers in the differentiation of pancreatitis from controls.

show abstract

In Search for a Better Marker of Acute Pancreatitis—Third Time Lucky?

Cited by 11 publications

References 14 publications

Serological diagnosis and prognosis of severe acute pancreatitis by analysis of serum glycoprotein 2

Serological diagnosis and prognosis of severe acute pancreatitis by analysis of serum glycoprotein 2

Role of total calcium and corrected calcium in comparisons with computed tomography to predict severity of acute pancreatitis

Phospholipase A2 as a point of care alternative to serum amylase and pancreatic lipase

Contact Info

Product

Resources

About